Sign in
CompletedNo phase

Molecular Panel Evaluation for Diagnosis of Infections of the Central Nervosous System

Key facts

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
170 people enrolled
Started
17 Apr 2024
Ended
31 Dec 2024
Type of study
Observational
Treatments tested
  • QIAstat-Dx®Meningitis/Encephalite Panel
Record updated
18 December 2025

Who can take part

Sex
Women and men
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • 170 samples of CSF positive for virus and/or bacteria
  • Samples stored at -80°C, less than 5 years
  • Samples with a volume of at least 800μL

Who cannot take part

  • Samples of a different matrix than CSF
  • Samples stored at room temperature
  • Samples for which diagnostic test results are not available
  • Samples with a volume of less than 800μL
  • Samples already thawed and refrozen

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Infections involving the central nervous system (CNS), such as meningitis/encephalitis (ME), are serious clinical conditions associated with high morbidity and mortality rates, as well as significant long-term consequences. ME can be caused by a wide variety of pathogenic agents. Clinical symptoms may vary and it has been shown that early identification of the pathogens causing ME allows for timely and appropriate treatment, thus reducing permanent neurological damage. The multiparameter panel "QIAstat-Dx®Meningitis/Encephalitis" can detect in one hour on a sample of 15 bacterial, viral and fungal pathogens. In the diagnostic routine, Real-time PCR takes an average of 3 hours and culture examination 2 days. In addition, compared to other comparable rapid molecular systems, the "QIAstat-Dx" platform has the ability to generate a cycle-related threshold value (Ct) for the targets detected. This value may have a correlation with the viral load and thus provide in a short time not only the result of positivity, but also an indication of the amount of virus present. Other commercially available multiparameter molecular tests provide only qualitative data.

The group in the trial

  • Positive Samples

    Positive samples for viruses or bacteria typical of meningitis/encephalitis

    Treatment: QIAstat-Dx®Meningitis/Encephalite Panel

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multiparametric Molecular Panel Evaluation "QIAstatDxMeningitis/Encephalitis" for Diagnosis of Infections of the Central Nervosous System
Record updated
18 December 2025